Unknown

Dataset Information

0

Risk-adapted, ofatumumab-based chemoimmunotherapy and consolidation in treatment-naive chronic lymphocytic leukemia: a phase 2 study.


ABSTRACT: High-risk cytogenetics and minimal residual disease (MRD) after chemoimmunotherapy (CIT) predict unfavorable outcome in chronic lymphocytic leukemia (CLL). This phase 2 study investigated risk-adapted CIT in treatment-naïve CLL (NCT01145209). Patients with high-risk cytogenetics received induction with fludarabine, cyclophosphamide, and ofatumumab. Those without high-risk cytogenetics received fludarabine and ofatumumab. After induction, MRD positive (MRD+) patients received 4 doses of ofatumumab consolidation. MRD negative (MRD-) patients had no intervention. Of 28 evaluable for response, all responded to induction and 10 (36%) achieved MRD-. Two-year progression-free survival (PFS) was 71.4% (CI95, 56.5-90.3%). There was no significant difference in median PFS between the high-risk and the standard-risk groups. Ofatumumab consolidation didn't convert MRD + to MRD-. In the MRD + group, we saw selective loss of CD20 antigens during therapy. In conclusion, risk-adapted CIT is feasible in treatment-naïve CLL. Ofatumumab consolidation didn't improve depth of response in MRD + patients. Loss of targetable CD20 likely reduces efficacy of consolidation therapy.

SUBMITTER: Desai S 

PROVIDER: S-EPMC9250410 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC4981588 | biostudies-literature
| S-EPMC5530057 | biostudies-other
| S-EPMC3262343 | biostudies-literature
| S-EPMC6221114 | biostudies-literature
| S-EPMC3894149 | biostudies-literature
| S-EPMC8670015 | biostudies-literature
| S-EPMC4380724 | biostudies-literature
| S-EPMC6908306 | biostudies-literature
| S-EPMC7430864 | biostudies-literature
| S-EPMC3262337 | biostudies-literature